temporal

We are pleased to announce that the findings from our recent acromegaly and NETs global survey have been published in Advances in Therapy, in the paper titled:

 

Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours

 

The scientific committee surveyed patients, HCPs and non-HCP caregivers to assess current opinion surrounding SRL device attributes associated with the most favourable injection experience for people living with acromegaly and neuroendocrine tumours (NETs).

The findings identify the key features of injection devices for SRL therapy and underscore the importance of involving patients in treatment decisions.

Read the publication, download the survey overview and get the key clinical takeaways below.

 


 

Clinical Takeaways

 

  • Attributes that significantly impact the treatment experience for both patients and caregivers include ease and confidence of device use, device safety with a focus on minimising contamination risks and less burdensome injections

  • The survey underscores the need to boost confidence in administering SRL injections for non-HCP caregivers and self-injecting patients. Achieving this involves device-specific training, patient education, instructional videos, online resources, and continued support from HCPs

  • Patient and caregiver opinions play a crucial role in advancing device design, enabling shared decision-making, and selecting suitable injection devices tailored to individual therapeutic requirements

Scientific Committee

Dr Jens Otto Lunde Jørgensen, Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

Prof. Wouter de Herder, Department of Internal Medicine-Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands

Mrs Wendy Martin, King's College Hospital, London, UK

Ms Teodora Kolarova, International Neuroendocrine Cancer Alliance (INCA), Boston, MA, USA

Ms Muriël Marks, World Alliance of Pituitary Organizations (WAPO), Amsterdam, Netherlands

Ms Cecilia Follin, Lund University Cancer Centre, Lund, Sweden

Ms Wanda Geilvoet, Department of Internal Medicine-Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands

Prof. Shlomo Melmed, Pituitary Center, Dept of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Programme summary
Share this programme
Educational programme supported by an independent medical education grant from Ipsen
Endorsement
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.